| General information |
| Database: | DB00612 |
| Objective: | They evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries. |
| Authors: | Reardon DA, et al |
| Title: | Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. |
| Journal: | Br J Cancer. |
| Year: | 2012 |
| PMID: | 23037712 |
| Trial Design |
| Clinical Trial Id: | retrospective pooled analysis |
| Agent: | bevacizumab
|
| Target: | Vascular endothelial growth factor
|
| Cancer Type: | Tumors of the nervous system |
| Cancer Subtype: | glioblastoma |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | retrospective pooled analysis |
| Key Patients Feature: | histopathological confirmation of grade IVmalignant glioma, recurrent disease following standard temozolomidebased chemoradiotherapy (Stupp et al, 2005), up to threeprior episodes of progressive disease, age X18 years, Karnofskyperformance status (KPS) X60, and adequate renal, hepatic andhaematologic function. |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | retrospective pooled analysis |
| Primary End Point: | NA |
| Secondary End Point: | NA |
| Patients Number: | 99 |
| Trial Results |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | NA |
| Median Time to Progression: | NA |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n 55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a nonbevacizumab regimen (n 44; P 0.014). |
| Adverse Event(agent arm): | NA |
| Conclusions: | he results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available nonbevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial. |